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The hormone hypothesis of male reproductive 
disorders suggests that both endogenous and 
exogenous hormones might be risk factors 
for cryptorchidism, hypospadias, impaired 
spermatogenesis, and testicular cancer (Sharpe 
2003). Exogenous hormonal exposures involve 
a variety of endocrine-disrupting chemicals 
whose effects range from estrogenic to anti-
estrogenic, androgenic, and antiandrogenic. 
Evidence in support of the hypothesis has 
consisted largely of animal data (Toppari et al. 
1996) and temporal trends (Paulozzi 1999) in 
the prevalence of the so-called testicular dys-
genesis syndrome (TDS) conditions. Human 
studies of the relationship between endocrine-
disrupting chemicals and the TDS disorders 
have been relatively few.
Polychlorinated biphenyl (PCB) com-
pounds are ubiquitous, stable, environmental 
pollutants that were widely used in devel-
oped countries between 1929 and 1977. Even 
after they were banned, PCBs continued 
to be used in “closed” source applications 
such as electrical capacitors and transform-
ers. Levels of PCBs in humans have declined 
since the 1960s but remain detectable in most 
segments of the population (Ross 2004). To 
date, only four published studies have exam-
ined the association between PCBs and either 
cryptorchidism or hypospadias. Two case–
control studies of PCBs and cryptorchidism 
reported no relationship with risk (Hosie 
et al. 2000; Mol et al. 2002), whereas a third 
offered meas  ured support (Brucker-Davis 
et al. 2008). One ecologic study of PCBs and 
hypospadias reported an inverse association 
(Giwercman et al. 2006). Because the prior 
studies may have been too small to detect 
statistically significant differences, the present 
study was conducted among a large, well-
described population in which the serum 
samples were collected at a time when PCB 
levels in the United States were higher.
Materials and Methods
Study population. The Collaborative Perinatal 
Project (CPP) was a prospective study of 
neurologic disorders and other conditions 
in children (Niswander and Gordon 1972). 
Pregnant women were enrolled between 1959 
and 1965 at 12 U.S. medical centers located in 
Baltimore, Maryland; Boston, Massachusetts; 
Buffalo, New York; Memphis, Tennessee; 
Minneapolis, Minnesota; New Orleans, 
Louisiana; New York City (two centers); 
Philadelphia, Pennsylvania; Portland, Oregon; 
Providence, Rhode Island; and Richmond, 
Virginia. Eleven centers recruited participants 
from the prenatal clinics of a university hos-
pital, whereas one (Buffalo) recruited from 
13 private obstetric practices. Participant 
selection varied among the medical centers. 
Women were ineligible if they were incarcer-
ated, planned to leave the area on delivery, or 
planned to place their child for adoption or if 
they delivered on the day they were recruited 
for the study. The characteristics of the women 
in the sample were, at registration, essen-
tially the same as those in the sampling frame 
(Niswander and Gordon 1972). Four per-
cent of the participants were lost to follow-up 
before delivery. Once enrolled, the women’s 
nonfasting blood was drawn approximately 
every 8 weeks during pregnancy, at delivery, 
and at 6 weeks postpartum. Sera were stored 
in glass vials at –20°C with no recorded thaws. 
Approximately 42,000 women were enrolled, 
and 55,000 children were born in the study. 
The children were systematically assessed 
for the presence of birth defects and other 
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Ba c k g r o u n d: The etiologies of the male urogenital anomalies cryptorchidism and hypospadias are 
poorly understood. It has been suggested, however, that in utero hormone levels may be related to 
risk. Endocrine-disrupting chemicals, including polychlorinated biphenyl (PCB) compounds, may 
alter hormone levels and thereby affect the fetus.
oBjectives: To examine whether in utero PCB exposure is related to cryptorchidism and hypo-
spadias, we examined PCB levels among pregnant women enrolled in the Collaborative Perinatal 
Project (CPP). 
Me t h o d s : The CPP enrolled pregnant women at 12 U.S. medical centers between 1959 and 1965. 
For the present research, we analyzed third-trimester serum samples from the mothers of 230 sons 
with cryptorchidism, 201 sons with hypospadias, and 593 sons with neither condition. We esti-
mated adjusted odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression and 
examined the associations of each anomaly with individual PCB congener levels, sum of PCBs, and 
several functional groupings of PCBs. 
re s u l t s: In general, the ORs for cryptorchidism or hypospadias showed no notable associations 
with individual PCB congener levels or functional groupings of PCBs. However, the ORs and 95% 
CIs for the sum of PCBs associated with hypospadias were as follows: 0–1.9 µg/L, reference group; 
2–2.9 µg/L, OR = 1.57, 95% CI, 1.05–2.34; 3–3.9 µg/L, OR = 1.45, 95% CI, 0.90–2.34; and 
≥ 4.0 µg/L, OR = 1.69, 95% CI, 1.06–2.68; p-value for trend = 0.08.
co n c l u s i o n s: Given the large number of associations examined, these findings do not strongly 
support the hypothesis that PCBs are associated with cryptorchidism or hypospadias. Because 
population serum PCB levels at the time of sample collection were considerably higher than levels 
at present, it is unlikely that current PCB exposure is related to the development of either anomaly.
key w o r d s : cryptorchidism, hypospadias, polychlorinated biphenyls, testicular dysgenesis syn-
drome. Environ Health Perspect 117:1472–1476 (2009).  doi:10.1289/ehp.0800389 available via 
http://dx.doi.org/ [Online 20 April 2009]PCBs and risk of hypospadias and cryptorchidism
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outcomes at birth and through 7 years of age. 
Follow-up to 7 years of age was completed for 
about 75% of children born into the study.
For the present study, we employed a 
nested case–control design to examine the 
association between maternal serum PCB 
levels and risk of cryptorchidism and hypo-
spadias among sons. To be eligible for inclu-
sion in the present study, the mother must 
have given birth to a singleton, live-born male 
infant and must have had a 3-mL aliquot of 
third-trimester maternal serum available. We 
defined cryptorchidism as having had a diag-
nosis of undescended testis(es) at any time 
during the first year of life. The diagnosis was 
made by pediatricians based on serial exami-
nations that included inspection and palpa-
tion of the genitalia. Boys first noted in the 
medical record to have undescended testis(es) 
after the first year of life were not considered 
cryptorchid because they may have had retrac-
tile testes. Hypospadias was defined as having 
a diagnosis any time during the first 7 years of 
life. Degree of hypospadias was not noted in 
the medical records.
Among the 28,444 boys in the CPP, 267 
were not live born and 441 were not singletons. 
No blood sample was available from the moth-
ers of 5,389 boys. Among the eligible 22,347 
boys, there were 241 cases of cryptorchidism 
and 214 cases of hypospadias. The five boys 
with both cryptorchidism and hypospadias 
were included in each group for the analysis. 
From the pool of eligible mothers, 599 were 
selected at random so that the control:case ratio 
would be > 2:1 for each condition.
Among the boys diagnosed as cryptorchid 
during the first year of life, the study records 
indicated that the testicles were descended at 
birth in 103, suggesting that these boys may 
have had acquired, rather than congenital, 
undescended testis (Barthold and Gonzalez 
2003). To evaluate whether a relationship 
with PCBs varied by type of cryptorchidism, 
we considered the boys with testis descended 
at birth separately in a sensitivity analysis. 
Among the boys with undescended testicle(s) 
at birth (n = 138), all but one also had a sub-
sequent observation of cryptorchidism in at 
least one of the three subsequent examination 
(ages 4 months, 1 year, 7 years) or documen-
tation of orchidopexy.
The socioeconomic index calculated 
for participants in the CPP was the mean 
of the three percentile scores: education of 
head of the household, occupation of head 
of the household or chief wage earner, and 
family income. The score used to calculate 
the percentile for an occupation was based 
on the percentiles of education and income 
among persons with the same occupation 
(Myrianthopoulos and French 1968). Verbal 
consent to participate was elicited from all 
mothers (Hardy 2003).
Laboratory assays. Serum levels of 11 PCBs 
were measured at the Centers for Disease 
Control and Prevention after solid-phrase 
extraction cleanup and dual-column gas chro-
matography using electron capture detection 
(Brock et al. 1996). The congeners, designated 
by International Union of Pure and Applied 
Chemistry code, were PCB-28, PCB-52, 
PCB-74, PCB-105, PCB-118, PCB-138, 
PCB-153, PCB-170, PCB-180, PCB-194, and 
PCB-203. The proportion of PCBs in each 
sample recovered by extraction was approxi-
mately 60%. The results shown are unadjusted 
for recovery. The between-assay coefficient of 
variation was 19% at 3.49 µg PCB. A labora-
tory result was not obtained for 3% of samples 
because the measured value did not meet the 
quality-control standards for acceptance. Thus, 
the PCB results were not available for 30 sam-
ples. Because PCBs are lipid soluble and because 
serum contains a variable amount of lipid, we 
measured serum cholesterol and   triglycerides 
using standing enzymatic assays.
In addition to analyzing each congener 
sepa  rately, we examined four groupings of con-
geners. The Wolff groupings (Wolff et al. 1997) 
were as follows: Wolff group 1A, potentially 
estrogenic, weak phenobarbital inducers, not 
persistent congeners (PCB-52); Wolff group 
2A, potentially antiestrogenic and immuno-
toxic, dioxin-like, non-ortho– and mono-ortho–
substituted, moderately persistent congeners 
(PCB-74, PCB-105, PCB-118); Wolff group 
2B, limited dioxin activity, di-ortho substituted, 
persistent congeners (PCB-138, PCB-170) and 
Wolff group 3, phenobarbital inducers, CYP1A 
and CYP2B inducers, and persistent congeners 
(PCB-153, PCB-180, PCB-203). The toxic 
equivalency factor (TEF) groupings (Ahlborg 
et al. 1994) were TEF mono-ortho (PCB-
105, PCB-118), and TEF di-ortho (PCB-170, 
PCB-180). The uridine diphosphate-glucurono-
syl transferase (UDP-GT) inducer, cytochrome 
P450 1A (CYP1A), and CYP2B inducer group-
ing (Chevrier et al. 2007) was PCB-118 and 
PCB-180. The molecular-weight groups were 
low (PCB-28, PCB-52, PCB-74, PCB-105, 
PCB-118) and high (PCB-138, PCB-153, 
PCB-170, PCB-180, PCB-194, PCB-203).
Statistical methods. We converted PCBs 
to molar concentrations (PCB in micrograms 
per liter divided by the congener’s molecu-
lar weight) and then analyzed on a continu-
ous scale. Five congeners had missing values 
(PCB-28, n = 2; PCB-74, n = 26; PCB-118, 
n = 42; PCB-138, n = 22; PCB-180, n = 2), 
mainly because the measured value did not meet 
the quality control standards for acceptance 
(Ballschmiter et al. 1992). We estimated the 
change in log odds of having cryptorchidism or 
hypospadias per millimole increase in PCB level 
using conditional logistic regression, condi-
tioned on study center (12 strata). Models were 
adjusted for serum triglycerides and   cholesterol 
as continuous variables and serum p,p´-dichloro-
diphenyldichloroethylene (p,p´-DDE) as a five-
stratum categorical variable.
We evaluated confounding by comparing 
the hazard ratio of the baseline model (includ-
ing sum of PCBs, triglycerides, cholesterol, and 
p,p´-DDE) to the hazard ratio of the model 
that also included the possible confounder. We 
modeled sum of PCBs both as a continuous 
variable and as a categorical variable and used 
results of both analyses to determine whether 
the factor was a confounder. If the hazard ratio 
per microgram per liter of PCB or the haz-
ard ratio for the contrast of highest-to-lowest 
PCB strata changed by 15% or more, the fac-
tor was considered a confounder. The factors 
considered as possible confounders were race, 
season of birth, maternal age, maternal parity, 
socioeconomic index, prepregnancy body mass 
index, weight gain during pregnancy, smoking 
during pregnancy, hyperemesis gravidarum, 
gestational hypertension, age at menarche, his-
tory of infertility, menstrual cycle irregularity, 
estrogen use during pregnancy, and progester-
one use during pregnancy. Similarly, we con-
sidered the effects of adjustment for preterm 
birth, birth weight, placental weight, and small-
for-gestational-age even though these were 
potentially intermediate variables. None of the 
factors considered, however, changed the hazard 
ratios by ≥ 15%. Using a similar approach, but 
with cross-product terms, we evaluated effect 
modification by maternal age, race, smoking, 
prepregnancy body mass index, triglycerides, 
cholesterol, serum p,p´-DDE, gestational hyper-
tension, socioeconomic index, and study center. 
We supplemented evaluation of effect modifica-
tion by categorical variables with more than two 
categories by comparing the model fit statistics 
for models with and without the cross-product 
terms. If the p-value associated with the inter-
action term based on the likelihood ratio test 
had a value ≤ 0.10, the degree of potential effect 
modification was further considered by examin-
ing tables stratified by the potentially modifying 
factor(s). We further evaluated sum of PCBs 
by forming ordinal categories and including 
corresponding dummy variables in the logistic 
regression analysis to estimate adjusted odds 
ratios (ORs). We performed trend tests across 
categories by including a single independent 
variable with integer scores corresponding to 
the categories testing the significance of the 
regression coefficient. All statistical analyses 
were conducted using the SAS statistical soft-
ware package, version 9.1 (SAS Institute Inc., 
Cary, NC). All p-values were two-sided.
Results
Based on the distribution of the controls, the 
study population was 46% white, 48% black, 
and 5.6% other racial/ethnic groups (primarily 
Hispanic and Asian) (Table 1). Birth weight 
and gestational age medians were typical of McGlynn et al.
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healthy births. The mothers were a median age 
of 22 years and had a median socioeconomic 
index (mean of three percentile scores: educa-
tion of head of household, occupation of head 
of household or chief wage earner, and family 
income) of 4.5, which was just under of the 
median of 5.0 for the United States population 
in the 1960s. About 31% of the mothers were 
primiparas. Compared with the control boys, 
the boys with cryptorchidism and hypospadias 
were more likely to be white, to be born pre-
maturely, and to be born small for gestational 
age (birth weight below 10th percentile). The 
boys with hypospadias also had a lower median 
birth weight than did the control boys. A 
previous report has described the study popula-
tion in detail (Longnecker et al. 2002).
Table 2 shows median maternal PCB lev-
els, lipid levels, and DDE levels for each of 
the study groups. The median level of sum 
of PCBs was slightly lower in the controls 
(2.7 µg/L), whereas the median levels of 
p,p´-DDE (24.5 µg/L) and total cholesterol 
(234 µg/L) were slightly higher. The median 
level of triglycerides in the controls (204 µg/L) 
was intermediate to the two case groups.
Table 3 shows the adjusted ORs for the 
PCB congener-specific analyses, conditioned 
on study center and adjusted for triglyc-
erides, cholesterol, and p,p´-DDE level. For 
cryptorchidism, the ORs ranged from 1.03 
(PCB-118) to 1.79 (PCB-203), and none 
were statistically significant. For hypospadias, 
the ORs ranged from 0.80 (PCB-52) to 1.99 
(PCB-203), and as with cryptorchidism, none 
were statistically significant.
Table 3 also shows the adjusted ORs for 
groupings of PCBs. We found no significant 
increase in risk of either cryptorchidism or 
hypospadias with increasing level of sum of 
PCBs [cryptorchidism: OR = 1.01, 95% con-
fidence interval (CI), 0.99–1.04; hypospadias: 
OR = 1.01, 95% CI, 0.98–1.04]. Similarly, we 
found no significant increases in risk of either 
outcome with any of the Wolff groupings 
(Wolff et al. 1997), TEF groupings (Ahlborg 
et al. 1994), or enzyme inducer (Chevrier 
et al. 2007) groupings. Because the ORs in the 
congener-specific analysis tended to be higher 
among the higher-molecular-weight congeners, 
we also analyzed PCBs stratified by molecular 
weight. The analyses did not detect statistically 
significant associations with either cryptorchid-
ism (low: OR = 1.02, 95% CI, 0.97–1.06; 
high: OR = 1.04, 95% CI, 0.98–1.09) or hypo-
spadias (low: OR = 1.00, 95% CI, 0.95–1.06; 
high: OR = 1.04, 95% CI, 0.98–1.10).
Because the examinations of cryptorchid-
ism and hypospadias with the sum of PCBs 
approached statistical significance, we also 
analyzed risk by PCB category (Table 4). 
Cryptorchidism was not significantly related 
to PCB level in any category, and the test for 
trend was not statistically significant (p for 
trend = 0.19). The results of a similar analysis 
that modeled sum of PCBs on a lipid basis 
in quintiles produced the same conclusions 
(data not shown). Although the trend in risk 
of hypospadias approached significance (p for 
trend = 0.08) and the ORs for all categories 
were greater than unity, we found, overall, no 
linear relationship. The examination of effect 
modification showed that no factor signifi-
cantly altered the results of the baseline models 
(data not shown). A final examination of cryp-
torchidism excluded the boys (n = 103) whose 
testicles were initially descended at birth. 
The results of that analysis (data not shown), 
however, did not differ from the analysis that 
included all boys with cryptorchidism.
Discussion
The results of the present study do not support 
the hypothesis that in utero PCB exposure 
increases the risk of hypospadias or cryp-
torchidism. Because the present study samples 
were collected in the 1960s, when PCB expo-
sure was substantially greater than at present, 
the results also suggest that current low-level 
PCB exposure is unlikely to be related to the 
development of either condition.
With the inclusion of > 1,000 participants, 
the present study is by far the largest to have 
examined the relationship between PCBs and 
Table 1. Characteristics of mothers and sons according to the son’s case–control status, CPP, 1959–1965.
Characteristic Cryptorchidism (n = 230) Hypospadias (n = 201) Control (n = 593)
Race (%) 
  White 57.0 49.3 46.0
  Black 41.3 44.8 48.4
  Other 1.7 6.0 5.6
Gestation (week)
  Median (Q1, Q3) 39 (38, 41) 39 (38, 41) 39 (38, 40)
Preterm birth (%) 16.6 19.5 14.0
Birth weight (g)
  Median (Q1, Q3) 3,260 (2,835, 3,629) 3,147 (2,665, 3,487)  3,260 (2,948, 3,600)
Small for gestational age (%) 9.1 17.8 4.9
Maternal age (years)
  Median (Q1, Q3) 24 (21, 30) 24 (20, 29) 22 (20, 28)
Previous live births (%) 
 0 27.0 30.8 30.9
 1 22.2 21.4 22.5
  ≥ 2 50.9 47.8 46.6
Socioeconomic index
  Median (Q1, Q3) 4.7 (3.3, 6.3) 4.3 (3.0, 6.2) 4.5 (3.3, 6.0)
Prepregnancy body mass index
  Median (Q1, Q3) 22.2 (20.3, 25.0) 21.8 (19.3, 24.1) 22.2 (20.0, 24.9)
Gestational hypertension (%) 5.9 6.5 6.4
Study Center (%)
  Boston, MA 31.3 25.4 23.6
  Buffalo, NY 7.0 3.5 3.5
  New Orleans, LA 6.5 3.5 4.7
  New York City, NYa 3.0 4.5 3.2
  Baltimore, MD 6.1 6.5 7.6
  Richmond, VA 7.0 5.5 5.7
  Minneapolis, MN 3.5 4.0 5.2
  New York City, NYb 1.7 6.0 7.8
  Portland, OR 4.3 5.5 7.1
  Philadelphia, PA 14.8 23.9 18.5
  Providence, RI 11.3 10.0 5.9
  Memphis, TN 3.5 2.0 7.1
aColumbia-Presbyterian Medical Center. bNew York Medical College
Table 2. Maternal serum values by son’s case–control status, CCP, 1959–1965.
Cryptorchidism (n = 230) Hypospadias (n = 201) Control (n =593)
Total cholesterol (ug/L)
  Median 231 229 234
  (Q1, Q3) (190, 272) (190, 275) (195, 279)
Triglycerides (ug/L)
  Median 207.5 187 204
  (Q1, Q3) (163, 258) (152, 253) (159, 259)
DDE (ug/L)
  Median 23.6 23.9 24.5
  (Q1, Q3) (15.9, 35.3) (16.2, 34.4) (16.7, 37.2)
Sum of PCBs with imputed congener (ug/L)
  Median 2.8 2.9 2.7
  (Q1, Q3) (2.0, 3.9) (2.1, 4.2) (1.8, 3.8)PCBs and risk of hypospadias and cryptorchidism
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cryptorchidism or hypospadias. Although the 
prior literature is not extensive, three studies 
of cryptorchidism and PCBs and one study of 
hypospadias and PCBs have been published. 
Mol et al. (2002) examined cord blood PCB 
levels in a population known to have high 
PCB exposure via fish consumption. Studying 
196 Faroe Island boys born between 1986 
and 1987, the investigators found no relation-
ship between PCB levels and cryptorchidism. 
A similar conclusion was reached by Hosie 
et al. (2000). Studying adipose PCB levels in 
18 German boys with cryptorchidism and 
30 control boys, the investigators found no dif-
ference in PCB levels. A third study examined 
PCB levels in both cord blood and breast milk 
in a French population (Brucker-Davis et al. 
2008). The comparison of 78 boys diagnosed 
at birth with cryptorchidism and 86 control 
boys found a significant association with breast 
milk PCB levels but not with cord blood PCB 
levels. When they restricted the analysis to the 
boys who remained cryptorchid at 3 months, 
however, the relationship with breast milk PCB 
levels was no longer significant. The only prior 
study of hypospadias and PCB levels reported 
to date was an ecologic study in Greenland. 
The investigators found a low prevalence rate of 
hypospadias despite high levels of PCBs in the 
population (Giwercman et al. 2006), suggest-
ing that PCBs might be inversely, rather than 
directly, associated with risk of hypospadias.
PCBs have been suspected of being 
related to male urogenital anomalies princi-
pally because some congeners and metabo-
lites display weak estrogenic activity. There is 
no evidence in the present results, however, 
that estrogenic activity is a risk factor. The 
  lower-molecular-weight congeners have greater 
estrogenic activity than the higher-molecular-
weight congeners (Wolff et al. 1997), yet it 
was the higher-molecular-weight congeners 
that had the greatest, although nonsignificant, 
ORs. In addition, it has been noted that the 
estrogenic potency of PCBs is extremely low 
compared with naturally occurring estrogens, 
so exposure may have little ability to affect the 
in utero estrogenic milieu (Safe 1995). In addi-
tion to estrogenic effect, there is evidence that 
PCBs also may have anti  androgenic effects, 
although the data are few and inconsistent 
(Ulbrich and Stahlmann 2004). Reduced 
anogenital distance has been reported, as 
has interference by PCB-138 with androgen 
receptor–mediated effects (Bonefeld-Jorgensen 
et al. 2001; Portigal et al. 2002; Schrader and 
Cooke 2003). Coplanar PCBs may also have 
antiandrogenic effects (Mocarelli et al. 2008). 
Although no coplanar PCBs were measured in 
the present study, their levels generally corre-
late well with sum of PCB levels (Gladen et al. 
1999; Longnecker et al. 2000).
If PCBs are able to alter the maternal   
hormonal milieu, it is possible that they 
would also be related to the TDS disorders 
(Skakkebaek et al. 2001) that become evident 
in adulthood: impaired spermatogenesis and 
testicular cancer. More studies have examined 
the relationship of PCBs with the former than 
the latter. In general, the results of the PCB–
fertility studies are somewhat equivocal. Several 
studies have found statistically significant associ-
ations with impaired sperm parameters (Hauser 
et al. 2003; Richthoff et al. 2003; Rozati et al. 
2002), whereas others have found no associa-
tion (Weiss et al. 2006) or associations only in 
subsets of their populations (Bush et al. 1986; 
Dallinga et al. 2002; Rignell-Hydbom et al. 
2004). In contrast, several studies have reported 
direct associations between PCB levels and fer-
tility (Cok et al. 2008; Ensslen et al. 1990). 
The summary of the international INUENDO 
study of PCBs and fertility in four populations, 
however, concluded that PCBs did not appear 
to affect fertility or to have direct hormone-
like activity (Bonde et al. 2008). To date, the 
sole published study of testicular cancer and 
PCBs found no association with sum of PCBs, 
estrogenic PCBs, or enzyme-inducing PCBs 
(Hardell et al. 2003). Taken as a group, then, at 
the present time, there is little evidence that the 
TDS disorders are related to PCB exposure.
Several potential weaknesses of the present 
study merit consideration. A first consideration 
is that the assays were run on stored, rather 
than fresh, serum samples. PCB levels, how-
ever, are quite stable over time, as has been 
demonstrated in samples stored for 15 years 
(Lunden and Noren 1998; Noren 1988). In 
addition, the cholesterol and triglyceride levels, 
as reported in Table 2, were in the expected 
range, suggesting that substantial degradation 
had not occurred. A second potential weakness 
is that determination of one of the outcomes, 
Table 4. Adjusted ORs (95% CIs) for cryptorchidism and hypospadias in relation to total PCB level in mater-
nal serum, CPP, 1959–1965.
Control Cryptorchism Hypospadias
Total PCBs (ug/L) (no.) No. Adjusteda OR (95% CI) No. Adjusteda OR (95% CI)
0–1.9 180 55 1.00 41 1.00
2–2.9 171 72 1.27 (0.88–1.83) 67 1.57 (1.05–2.34)
3–3.9 111 48 1.32 (0.86–2.02) 38 1.45 (0.90–2.34)
≥ 4.0 131 55 1.41 (0.90–2.20) 55 1.69 (1.06–2.68)
p-Trendb   0.19 0.08
aAdjusted for serum DDE concentration (five categories), triglycerides, and cholesterol. bOrdinal test across four categories, 
using the median value within each group.
Table 3. Adjusted ORs (95% CIs) for cryptorchidism and hypospadias in relation to maternal PCB levels 
(mmol/L), CPP, 1959–1965.
Percentiles among controls Cryptorchidism Hypospadias
  25th 50th 75th 95th Adjusteda OR (95% CI) Adjusteda OR (95% CI)
PCB congener
  PCB-28 0.39 0.70 0.97 1.79 1.07 (0.86–1.34) 1.07 (0.86–1.32)
  PCB-52 0.00 0.00 0.00 0.51 1.11 (0.81–1.52) 0.80 (0.42–1.52)
  PCB-74 0.51 0.79 1.13 2.16 1.04 (0.87–1.25) 1.03 (0.84–1.26)
  PCB-105 0.00 0.34 0.52 1.19 1.11 (0.82–1.50) 1.03 (0.69–1.53)
  PCB-118 1.13 1.65 2.39 5.21 1.03 (0.95–1.12) 0.99 (0.88–1.11)
  PCB-138 1.16 1.61 2.36 3.85 1.09 (0.94–1.25) 1.08 (0.93–1.26)
  PCB-153 1.22 1.69 2.52 4.02 1.11 (0.97–1.27) 1.12 (0.98–1.30)
  PCB-170 0.00 0.23 0.38 0.66 1.07 (0.59–1.94) 1.34 (0.73–2.46)
  PCB-180 0.35 0.56 0.83 1.39 1.19 (0.84–1.69) 1.28 (0.89–1.84)
  PCB-194 0.00 0.00 0.21 0.37 1.42 (0.54–3.72) 1.41 (0.48–4.19)
  PCB-203 0.00 0.00 0.21 0.42 1.79 (0.71–4.52) 1.99 (0.75–5.28)
Sum of PCBs 5.29 7.86 10.92 19.48 1.01 (0.99–1.04) 1.01 (0.98–1.04)
UPD-GT inducers 1.44 2.15 3.12 6.19 1.03 (0.96–1.11) 1.01 (0.92–1.11)
Wolff groups
  1A 0.00 0.00 0.00 0.51 1.11 (0.81–1.52) 0.80 (0.42–1.52)
  2A 1.78 2.61 3.75 8.06 1.02 (0.97–1.07) 1.00 (0.94–1.07)
  2B 1.22 1.75 2.66 4.41 1.07 (0.94–1.21) 1.07 (0.94–1.22)
 3 1.59 2.30 3.49 5.59 1.08 (0.98–1.18) 1.09 (0.98–1.20)
TEF Groups
  Mono-ortho 1.19 1.93 2.85 6.13 1.02 (0.96–1.10) 0.99 (0.91–1.09)
  Di-ortho 0.38 0.73 1.21 1.97 1.09 (0.87–1.38) 1.16 (0.92–1.48)
Molecular weight groups
  Low 2.31 3.36 4.68 9.98 1.02 (0.97–1.06) 1.00 (0.95–1.06)
  High 2.8 4.21 6.32 10.27 1.04 (0.98–1.09) 1.04 (0.98–1.10)
aResults are from conditional logistic regression, conditioned on study center and adjusted for serum DDE level (5 strata), 
triglycerides, and cholesterol. OR is change in lnOR per mmol/L increase in PCB.McGlynn et al.
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cryptorchidism, can be problematic. A sin-
gle determination of testicular descent in the 
delivery room is not always accurate. Testes 
descend late in the third trimester and are not 
uncommonly undescended at birth. In addi-
tion, it is now generally acknowledged that 
“acquired undescended testes” does occur, 
although the age at occurrence remains a mat-
ter of some debate (Barthold 2008). However, 
the CPP examined the children systematically 
over time to ascertain congenital anomalies 
(Myrianthopoulos and Chung 1974). As a 
result, the rates of both cryptorchidism and 
hypospadias reported in the CPP were higher 
(Myrianthopoulos and Chung 1974) than 
they were other U.S. studies (Paulozzi 1999). 
For the present study, the ratio of hypo  spadias 
to cryptorchidism was somewhat higher 
than might be expected because we included 
hypospadias diagnosed up until 7 years of age, 
whereas we excluded cryptorchid cases diag-
nosed after 1 year. A final limitation of the 
study was that the medical records did not note 
degree of hypospadias among the boys affected.
In conclusion, the results of the present 
study do not support an association between 
in utero PCB exposure and either cryptorchid-
ism or hypospadias. PCBs are just one type 
of environmental endocrine modulator, how-
ever. Whether other endocrine modulators 
are related to risk is unclear and should be 
examined in other studies.
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